Matthew B. Harms, MD, Associate Professor of Neurology, and Neil A. Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders (in Neurology) comment on ALS research
Neil Shneider, MD, PhD, Claire Tow Associate Professor of Neurology, talks about the new approved tofersen (Qalsody), the first drug developed for patients with a rare form of ALS
Dr. Jinsy Andrews, associate professor of neurology at CUIMC, commented on the newly approved oral drug to treat amyotrophic lateral sclerosis (ALS), a nervous system disease that weakens muscles
Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is now being tested in ALS patients
Six Columbia University scientists have received NIH High-Risk, High-Reward grants that are given to exceptionally creative scientists proposing unconventional, but potentially high-impact, research
Neil Shneider, Stockman-Mauriello’s doctor and director of the Eleanor and Lou Gehrig ALS Center at Columbia University in New York, nonetheless asked Biogen for access.